Latest Revenue Guidance News

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

Fluence Corporation reported a robust 64.7% revenue increase in the first half of 2025, driven by strong project execution in Ivory Coast and growth in key business units. Despite tariff uncertainties and a cautious China outlook, the company maintains its full-year guidance and eyes further backlog expansion.

Fluence Corporation reports a robust 64.7% revenue increase in H1 2025, driven by strategic focus on higher-margin Smart Product Solutions and recurring revenue streams. The company maintains its FY2025 guidance, supported by a strong backlog and progress on a major Ivory Coast water project.

Enlitic, Inc. has confirmed its commitment to achieving operational cashflow break-even by the end of 2025, alongside maintaining its revenue guidance of US$9-11 million for the calendar year.

Appen Limited reported a mixed Q2 FY25 with a 6% revenue decline year-over-year, driven by a strong 77% surge in its China business that achieved profitability, while US market challenges persist. The company targets $10 million in cost savings to fuel future growth.

Aroa Biosurgery has reported its third consecutive quarter of positive net cash flow, maintaining a strong cash position and reaffirming its FY26 revenue and EBITDA guidance. The company’s Myriad product sales continue to grow, supported by new clinical evidence.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

Mach7 Technologies has updated its FY25 guidance, reporting positive cash flow and a solid financial position, while appointing Teri Thomas as its new CEO to steer the company’s next growth phase.

Mach7 Technologies closes FY25 with solid recurring revenue growth, positive cash flow, and a refreshed leadership team focused on innovation and customer value.

Mastermyne Group forecasts a significant revenue decline for FY25 due to mine suspensions and closures but reports a stronger net cash position and early signs of operational recovery.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Ava Risk Group reports a 5% revenue increase and a positive EBITDA turnaround in FY25, underpinned by its advanced security technologies. The company eyes over $88 million in FY26 sales opportunities despite some project delays.